Abstract
SAT425 - A once-per-week or every-two-week dosing regimen is more efficacious for the TIR7 agonist JNJ-64794964 (JNJ-4964) to induce an anti-hepatitis B virus (HBV) effect and HBV-specific immune responses in AAV-HBV mice
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.